Nested case/control study: OR of HL, by markers of immunodeficiency at 2 different time periods before diagnosis
| . | 1-2 years before HL . | Within 1 year before HL . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HL . | Matched controls . | OR* (95% CI) . | HL . | Matched controls . | OR* (95% CI) . | |||||||
| n . | (%) . | n . | (%) . | . | n . | (%) . | n . | (%) . | . | |||
| Overall | 47 | 444 | 47 | 444 | ||||||||
| Total lymphocyte count, cells/μL | ||||||||||||
| 2000 or more | 14 | (36.8) | 128 | (39.3) | 1 | 3 | (7.3) | 132 | (34.6) | 1 | ||
| 1000-1999 | 21 | (55.3) | 163 | (50.0) | 1.10 (0.53-2.31) | 21 | (51.2) | 197 | (51.6) | 5.81 (1.68-20.1) | ||
| 0-999 | 3 | (7.9) | 35 | (10.7) | 0.71 (0.18-2.78) | 17 | (41.5) | 53 | (13.9) | 21.0 (5.44-81.0) | ||
| Unknown | 9 | 118 | 6 | 62 | ||||||||
| Per 500/μL decrease | 0.96 (0.78-1.19) | 1.91 (1.43-2.56) | ||||||||||
| CD4+ cell count, cells/μL | ||||||||||||
| 500 or more | 13 | (34.2) | 126 | (38.1) | 1 | 3 | (7.3) | 136 | (35.3) | 1 | ||
| 200-499 | 17 | (44.7) | 151 | (45.6) | 1.10 (0.52-2.36) | 14 | (34.2) | 177 | (46.0) | 3.65 (1.02-9.55) | ||
| 50-199 | 8 | (21.1) | 47 | (14.2) | } | 1.24 (0.45-3.44) | 18 | (43.9) | 50 | (13.0) | } | 18.0 (5.06-63.7) |
| 0-49 | 0 | (0.0) | 7 | (2.1) | 6 | (14.6) | 22 | (5.7) | ||||
| Unknown | 9 | 113 | 6 | 59 | ||||||||
| Per 100/μL decrease | 1.08 (0.94-1.25) | 1.65 (1.33-2.03) | ||||||||||
| CD8+ cell count, cells/μL | ||||||||||||
| 1000 or more | 16 | (42.1) | 122 | (36.9) | 1 | 5 | (12.2) | 133 | (34.7) | 1 | ||
| 500-999 | 15 | (39.5) | 158 | (47.7) | 0.73 (0.35-1.52) | 17 | (41.5) | 192 | (50.1) | 2.66 (0.96-7.41) | ||
| 0-499 | 7 | (18.4) | 48 | (14.5) | 1.09 (0.41-2.89) | 19 | (46.3) | 58 | (15.2) | 11.1 (3.69-33.6) | ||
| Unknown | 9 | 116 | 6 | 61 | ||||||||
| Per 100/μL decrease | 0.96 (0.91-1.02) | 1.21 (1.09-1.34) | ||||||||||
| CD4+/CD8+ ratio, % | ||||||||||||
| 50 or more | 13 | (34.2) | 151 | (46.0) | 1 | 16 | (39.0) | 167 | (43.6) | 1 | ||
| 25-49 | 11 | (29.0) | 111 | (33.8) | 1.20 (0.52-2.79) | 13 | (31.7) | 133 | (34.7) | 0.96 (0.44-2.08) | ||
| 0-24 | 14 | (36.8) | 66 | (20.1) | 2.44 (1.05-5.70) | 12 | (29.3) | 83 | (21.7) | 1.47 (0.65-3.31) | ||
| Unknown | 9 | 116 | 6 | 61 | ||||||||
| Per 10% decrease | 1.07 (0.96-1.19) | 1.03 (0.94-1.13) | ||||||||||
| CD4+ percentage | ||||||||||||
| 26 or more | 11 | (32.4) | 117 | (40.6) | 1 | 12 | (30.8) | 146 | (41.8) | 1 | ||
| 14-25 | 13 | (38.2) | 124 | (43.1) | 1.14 (0.50-2.59) | 15 | (38.5) | 143 | (41.0) | 1.28 (0.58-2.83) | ||
| 0-13 | 10 | (29.4) | 47 | (16.3) | 2.07 (0.81-5.31) | 12 | (30.8) | 60 | (17.2) | 2.16 (0.89-5.26) | ||
| Unknown | 13 | 156 | 8 | 95 | ||||||||
| Per 10% decrease | 1.37 (0.96-1.96) | 1.57 (1.11-2.21) | ||||||||||
| CD8+ percentage | ||||||||||||
| 60 or more | 12 | (35.3) | 74 | (25.9) | 1 | 15 | (39.5) | 90 | (26.8) | 1 | ||
| 50-59 | 8 | (23.5) | 70 | (24.5) | 0.74 (0.26-1.39) | 7 | (18.4) | 99 | (29.5) | 0.40 (0.15-1.08) | ||
| 0-49 | 14 | (41.2) | 142 | (49.7) | 0.60 (0.26-1.39) | 16 | (42.1) | 147 | (43.8) | 0.64 (0.30-1.38) | ||
| Unknown | 13 | 158 | 9 | 108 | ||||||||
| Per 10% decrease | 0.80 (0.61-1.06) | 0.92 (0.71-1.19) | ||||||||||
| . | 1-2 years before HL . | Within 1 year before HL . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HL . | Matched controls . | OR* (95% CI) . | HL . | Matched controls . | OR* (95% CI) . | |||||||
| n . | (%) . | n . | (%) . | . | n . | (%) . | n . | (%) . | . | |||
| Overall | 47 | 444 | 47 | 444 | ||||||||
| Total lymphocyte count, cells/μL | ||||||||||||
| 2000 or more | 14 | (36.8) | 128 | (39.3) | 1 | 3 | (7.3) | 132 | (34.6) | 1 | ||
| 1000-1999 | 21 | (55.3) | 163 | (50.0) | 1.10 (0.53-2.31) | 21 | (51.2) | 197 | (51.6) | 5.81 (1.68-20.1) | ||
| 0-999 | 3 | (7.9) | 35 | (10.7) | 0.71 (0.18-2.78) | 17 | (41.5) | 53 | (13.9) | 21.0 (5.44-81.0) | ||
| Unknown | 9 | 118 | 6 | 62 | ||||||||
| Per 500/μL decrease | 0.96 (0.78-1.19) | 1.91 (1.43-2.56) | ||||||||||
| CD4+ cell count, cells/μL | ||||||||||||
| 500 or more | 13 | (34.2) | 126 | (38.1) | 1 | 3 | (7.3) | 136 | (35.3) | 1 | ||
| 200-499 | 17 | (44.7) | 151 | (45.6) | 1.10 (0.52-2.36) | 14 | (34.2) | 177 | (46.0) | 3.65 (1.02-9.55) | ||
| 50-199 | 8 | (21.1) | 47 | (14.2) | } | 1.24 (0.45-3.44) | 18 | (43.9) | 50 | (13.0) | } | 18.0 (5.06-63.7) |
| 0-49 | 0 | (0.0) | 7 | (2.1) | 6 | (14.6) | 22 | (5.7) | ||||
| Unknown | 9 | 113 | 6 | 59 | ||||||||
| Per 100/μL decrease | 1.08 (0.94-1.25) | 1.65 (1.33-2.03) | ||||||||||
| CD8+ cell count, cells/μL | ||||||||||||
| 1000 or more | 16 | (42.1) | 122 | (36.9) | 1 | 5 | (12.2) | 133 | (34.7) | 1 | ||
| 500-999 | 15 | (39.5) | 158 | (47.7) | 0.73 (0.35-1.52) | 17 | (41.5) | 192 | (50.1) | 2.66 (0.96-7.41) | ||
| 0-499 | 7 | (18.4) | 48 | (14.5) | 1.09 (0.41-2.89) | 19 | (46.3) | 58 | (15.2) | 11.1 (3.69-33.6) | ||
| Unknown | 9 | 116 | 6 | 61 | ||||||||
| Per 100/μL decrease | 0.96 (0.91-1.02) | 1.21 (1.09-1.34) | ||||||||||
| CD4+/CD8+ ratio, % | ||||||||||||
| 50 or more | 13 | (34.2) | 151 | (46.0) | 1 | 16 | (39.0) | 167 | (43.6) | 1 | ||
| 25-49 | 11 | (29.0) | 111 | (33.8) | 1.20 (0.52-2.79) | 13 | (31.7) | 133 | (34.7) | 0.96 (0.44-2.08) | ||
| 0-24 | 14 | (36.8) | 66 | (20.1) | 2.44 (1.05-5.70) | 12 | (29.3) | 83 | (21.7) | 1.47 (0.65-3.31) | ||
| Unknown | 9 | 116 | 6 | 61 | ||||||||
| Per 10% decrease | 1.07 (0.96-1.19) | 1.03 (0.94-1.13) | ||||||||||
| CD4+ percentage | ||||||||||||
| 26 or more | 11 | (32.4) | 117 | (40.6) | 1 | 12 | (30.8) | 146 | (41.8) | 1 | ||
| 14-25 | 13 | (38.2) | 124 | (43.1) | 1.14 (0.50-2.59) | 15 | (38.5) | 143 | (41.0) | 1.28 (0.58-2.83) | ||
| 0-13 | 10 | (29.4) | 47 | (16.3) | 2.07 (0.81-5.31) | 12 | (30.8) | 60 | (17.2) | 2.16 (0.89-5.26) | ||
| Unknown | 13 | 156 | 8 | 95 | ||||||||
| Per 10% decrease | 1.37 (0.96-1.96) | 1.57 (1.11-2.21) | ||||||||||
| CD8+ percentage | ||||||||||||
| 60 or more | 12 | (35.3) | 74 | (25.9) | 1 | 15 | (39.5) | 90 | (26.8) | 1 | ||
| 50-59 | 8 | (23.5) | 70 | (24.5) | 0.74 (0.26-1.39) | 7 | (18.4) | 99 | (29.5) | 0.40 (0.15-1.08) | ||
| 0-49 | 14 | (41.2) | 142 | (49.7) | 0.60 (0.26-1.39) | 16 | (42.1) | 147 | (43.8) | 0.64 (0.30-1.38) | ||
| Unknown | 13 | 158 | 9 | 108 | ||||||||
| Per 10% decrease | 0.80 (0.61-1.06) | 0.92 (0.71-1.19) | ||||||||||
Conditioned upon matching variables.